Ligand-targeted cancer therapeutics has been developed to minimize the non-specific cytotoxicity via ligand-drug conjugates during the past few decades.[1-3]We present here the design and synthesis of a GSH-activatable supramolecular photosensitizer conjugated with galactose (TPP-S-S-Gal) for targeted photodynamic therapy (PDT).